Future directions should include: (1) validation in human DN biopsy samples, (2) development of TCF3 knockout mouse models for more specific genetic manipulation, (3) investigation of TCF3 function at different DN stages, and (4) development of specific pharmacological TCF3 inhibitors for therapeutic translation. This evidence concerns the gene TCF3 and liver dysplastic nodule.